EXPRESSION GENIQUE COORDONNEE $i(IN VIVO)

Coordinate in vivo gene expression

Abstract

L'invention concerne des acides nucléiques, en particulier des produits de recombinaison d'ADN et des produits de transcription d'ARN, capables d'induire l'expression coordonnée de deux à trois cistrons, lors de leur introduction directe dans des tissus animaux. Parmi les polynucléotiques bi- ou tri-cistroniques de cette invention, on peut citer ceux codant et co-exprimant les produits géniques du VIH, des gènes codant des antigènes sans rapport avec le VIH, et des produits géniques immunostimulateurs dont, entre autres, GM-CSF, les interleukines, l'interféron et des membres de la famille B7 de protéines qui agissent comme éléments co-stimulants des lymphocytes T. Les polynucléotides et les procédés de cette invention sont utiles, d'une manière générale, pour coordonner l'expression in vivo de deux gènes ou d'avantage dans une seule cellule.
Nucleic acids, including DNA constructs and RNA transcripts, capable of inducing coordinate expression of two to three cistrons upon direct introduction into animal tissues, are presented. Bi- or tri-cistronic polynucleotides of this invention include those encoding and co-expressing HIV gene products, genes encoding antigens unrelated to HIV, and immunostimulatory gene products, including but not limited to GM-CSF, interleukins, interferon and members of the B7 family of proteins which act as T-cell costimulatory elements. The methods and polynucleotides of this invention are generally applicable to co-ordinate expression in vivo of any two or more genes in a single cell.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (2)

    Publication numberPublication dateAssigneeTitle
    WO-9311250-A1June 10, 1993British Technology Group Ltd.Bicistronic viruses
    WO-9404196-A1March 03, 1994Imperial Cancer Research Technology LimitedTherapie de tumeurs

NO-Patent Citations (3)

    Title
    B. WANG ET AL.;: "Gene inoculation generates immune responses against human immunodeficiency virus type 1", PROC. NATL. ACAD. SCI. USA, vol. 90, pages 4156 - 4160
    J. SMARDA AND J.S. LIPSICK: "Dicistronic selection for nuclear proteins in living animal cells", GENE, vol. 137, pages 145 - 149
    R.A. MORGAN ET AL.;: "Retroviral vectors containing putative internal ribosome entry sites: development of a poly- cistronic gene transfer system and applications to human gene therapy", NUCL ACIDS RES., vol. 20, pages 1293 - 1299

Cited By (27)

    Publication numberPublication dateAssigneeTitle
    US-8999380-B2April 07, 2015Moderna Therapeutics, Inc.Modified polynucleotides for the production of biologics and proteins associated with human disease
    US-9095552-B2August 04, 2015Moderna Therapeutics, Inc.Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
    US-9107886-B2August 18, 2015Moderna Therapeutics, Inc.Modified polynucleotides encoding basic helix-loop-helix family member E41
    US-9114113-B2August 25, 2015Moderna Therapeutics, Inc.Modified polynucleotides encoding citeD4
    US-9149506-B2October 06, 2015Moderna Therapeutics, Inc.Modified polynucleotides encoding septin-4
    US-9186372-B2November 17, 2015Moderna Therapeutics, Inc.Split dose administration
    US-9192651-B2November 24, 2015Moderna Therapeutics, Inc.Modified polynucleotides for the production of secreted proteins
    US-9216205-B2December 22, 2015Moderna Therapeutics, Inc.Modified polynucleotides encoding granulysin
    US-9220755-B2December 29, 2015Moderna Therapeutics, Inc.Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
    US-9220792-B2December 29, 2015Moderna Therapeutics, Inc.Modified polynucleotides encoding aquaporin-5
    US-9221891-B2December 29, 2015Moderna Therapeutics, Inc.In vivo production of proteins
    US-9233141-B2January 12, 2016Moderna Therapeutics, Inc.Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
    US-9254311-B2February 09, 2016Moderna Therapeutics, Inc.Modified polynucleotides for the production of proteins
    US-9271996-B2March 01, 2016Moderna Therapeutics, Inc.Formulation and delivery of PLGA microspheres
    US-9283287-B2March 15, 2016Moderna Therapeutics, Inc.Modified polynucleotides for the production of nuclear proteins
    US-9295689-B2March 29, 2016Moderna Therapeutics, Inc.Formulation and delivery of PLGA microspheres
    US-9301993-B2April 05, 2016Moderna Therapeutics, Inc.Modified polynucleotides encoding apoptosis inducing factor 1
    US-9303079-B2April 05, 2016Moderna Therapeutics, Inc.Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
    US-9334328-B2May 10, 2016Moderna Therapeutics, Inc.Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
    US-9428535-B2August 30, 2016Moderna Therapeutics, Inc.Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
    US-9447164-B2September 20, 2016Moderna Therapeutics, Inc.Engineered nucleic acids and methods of use thereof
    US-9464124-B2October 11, 2016Moderna Therapeutics, Inc.Engineered nucleic acids and methods of use thereof
    US-9533047-B2January 03, 2017Modernatx, Inc.Delivery and formulation of engineered nucleic acids
    US-9597380-B2March 21, 2017Modernatx, Inc.Terminally modified RNA
    US-9598469-B2March 21, 2017Novartis Vaccines And Diagnostics, Inc., University Of StellenboschHIV-1 south african subtype C env proteins
    US-9675668-B2June 13, 2017Moderna Therapeutics, Inc.Modified polynucleotides encoding hepatitis A virus cellular receptor 2
    US-9878056-B2January 30, 2018Modernatx, Inc.Modified polynucleotides for the production of cosmetic proteins and peptides